Member Info for Kev7722

£2?! I was promised £50/share and I’m not taking a penny less!

Seriously though, why all the sudden buyout speculation? Did I miss something today to suggest that an offer is imminent?

I also strongly believe we will get news next week... I don't think it's in the BODs interest at this point in time to be seen to be committing to a timeframe for news and then letting that time elapse without acknowledgement.

If the timeframe has slipped then as long as there is an adequate explanation then fair enough to some extent, and I don't actually think it will significantly damage the SP. I would however question how long they have been aware of delays, and whether they've carried on the positive rhetoric about timeframes during that time... I'd much rather be in the position Zen is in terms of being able to take what Faron (or any other small-cap) are telling us at face value, rather than questioning how truthful they are being...

Still happy with the long-term prospects here, but is it actually the case that the ‘time to get in here is now’? I only ask because HZM fairly recently announced the publication date of their BFS in advance, such was their level of confidence in the proposition - the market didn’t like the numbers and the SP tanked on release

Should be I agree, and yet the abusive messages seem to be a fairly regular occurrence :/

Anyway, 10 works days to go - as Zen likes to remind us, the news window is very small now and shrinking day by day. Next week could be interesting indeed...

As I already said I'm expecting news in the next 2 weeks as Faron have given no indication not to. It's a pointless question to ask after the fact, as we'd obviously know the answer.

When given a 3-month window for news to land at any time I think it's fair to start mooting the possibility alternative outcomes when we're 11 out of 13 weeks in and have had no news - especially when we've had instances of the company delaying news previously.

Are you concerned about working capital / liquidity specifically? If not then the value of assets recorded in the balance sheet is a total non-issue

Mani - the point about separate partners for both drugs is a really interesting one.

Something that I hadn't really considered until reading that just now - it seems widely accepted that there is a need to 'reboot' Traumakene in order to move forward with the drug (and an obvious cost attached to that exercise). If a partner is brought on specifically in relation to Clevergen then presumably any additional money that is put on the table would be ringfenced...?

To re-iterate, I'm still expecting YODA results in the next 12 working days as there has been no indication from Faron that I should expect otherwise.

Itsamess, Zen et al - I think everyone knows your views on a partner announcement being imminent and funding being a non-issue. My question though was whether no update on YODA, or an announcement that findings will be delayed until Q2 (which potentially kicks the can 3 months further down the road) is likely to have a short-term impact on the SP - do either of you have a view on that specifically?

Morning all,

Most are agreed that inconclusive YODA findings will damage the SP, but are there any thoughts on whether no news in line with their timeframe will have an impact? Just over 2 weeks of the quarter left now, but nothing in news or interviews to suggest any kind of issue/delay so I’m still expecting a YODA update any day now.

Even with the (minor) language barrier it’s blatantly obvious to me that he’s saying there are a number of potential partners lining up to look at the emerging data, and that his strong preference is for one of those to come onboard and put money on the table - he’s definitely not saying that a partner is already onboard.

And if the SP can bounce around a bit more before then I'll be equally happy :)

I’m not sure we can hold them to a specific timeframe for announcing a Clevergen partner Zen - they have to find one first, from the many said to be watching the emerging trial data ;)

Hi Dan,

Yes, that was my interpretation. What I think we're yet to see is enough evidence that it can be sufficiently effective when the mutation isn't present.

Dan - I don't necessarily disagree with you, hence my comment that the Japanese partner may have a different view based on the data that is yet to come.

It does look as though Faron have all but confirmed that the drug is viable in cases where the mutation is present and there is no steroid interference... the size of the potential market is going to hinge on whether they can prove it is still viable when the mutation isn't present if there is no steroid interference.

Comments like the one in the proactive article ("Traumakine is a smaller opportunity now but still substantial for Faron") suggest to me that we shouldn't take that as a given however.

I'm less convinced now that the Japanese partner will pick this up, as there isn't really an Asian market for the drug... although I appreciate that it is possible as they are already invested here and may take a different view (we still don't have visibility of their data).

Even post-YODA, additional trials etc. I don't think we can rely on Traumakene alone to restore the battered SP. As the proactive article correctly notes, 'Traumakine is a smaller opportunity now but still substantial for Faron'. I'm still targeting a SP of around £3-3.50 medium term based on Traumakene progress alone (which is still a significant upside on today).

Clevergen is much higher risk, remains very much a long-term play, but the potential upside there now far outweighs anything we may see on Traumakene (IMO)

cwebb07 - definitely agree that they are looking to secure a partner soon. They seem pretty confident that they will be able to snap up one of the 'many said to be watching' - hence their stating that they will not need to raise funds via the market.

Zen - what is your insistence on constantly posting that one line from the article? I can't work out if it's just you taking it out of context or if you know exactly what you are doing and want others to take it out of context... full quote is as follows, and identifies the finding of a partner as being an inflection point for Faron:

“Inflection points:

More results from MATINS trial over a longer period

Faron finds a partner from the many said to be watching MATINS trial data

Traumakine reboots as a treatment for a specific type of ARDS sufferer who has a special type of genetic mutation known as C/T.”

If it makes you feel any better a load of my posts seem to have been deleted too, and they were pointing out that Mani was correct in pointing out that Faron currently have no partner for Clevergen... although the artice does point out that they claim to have multiple interested parties, and that securing a partner out of those would be an inflection point for the company.

I think you'd have to blame lazy admin to be honest - their approach seems to be to delete every reported post, rather than to actually review the content... otherwise we wouldn't have been left with a board full of defamatory posts about Mani ;)

What happened to all thechancers posts? They weren't remotely offensive... I was halfway through replaying to one!